688357-17-7

Upstream product

• 36404-88-3 2-chloro-3-carbaldehydepyridine 
• 688357-23-5 ethyl (2E)-(1-isopropenyl-6,7-dihydro-8H-pyrido[3,4-b]pyrrolizin-8-ylidene)ethanoate 
• 688357-24-6 ethyl (1-isopropyl-7,8-dihydro-8H-pyrido[3,4-b]pyrrolizin-8-yl)acetate 
• 688357-22-4 1-isopropenyl-6,7-dihydro-8h-pyrido[3,4-b]pyrrolizin-8-one 
• 688357-20-2 Methyl 1-chloro-8-oxo-7,8-dihydro-6H-pyrido[3,4-b]pyrrolizine-7-carboxylate 
• 688357-21-3 1-chloro-6,7-dihydro-8H-pyrido[3,4-b]pyrrolizin-8-one 
• 688357-18-8 2-azido-3-(2-chloro-3-pyridinyl)-2-propenoic acid methyl ester 
• 688357-19-9 4-chloro-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid methyl ester 
• 688357-25-7 ethyl (9-[(3,4-dichlorophenyl)thio]-1-isopropyl-7,8-dihydro-6H-pyrido[3,4-b]pyrrolizin-8-yl)acetate 

Downstream Products

• 1154034-43-1 C₂₂H₂₂Cl₂N₂O₂S 
• 887146-42-1 C₂₂H₂₂Cl₂N₂O₂S 
• 887146-43-2 (R)-methyl 3-[3-(3,4-dichlorophenylsulfanyl)-4-isopropyl-1H-pyrrolo[3,2-c]pyridin-2-yl]hexanoate 

Relevant academic research and scientific papers

Method of Treating Pathological Blushing

A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.

METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent

METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS

A method of treating atherosclerosis, dyslipidemia and related conditions is disclosed wherein a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof is administered to the patient in combination with a DP receptor antagonist. T

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention relates to niacin receptor agonists of formula: (I); as well as pharmaceutically acceptable salts and solvates. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.

Method of treating atherosclerosis, dyslipidemias and related conditions

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.

PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES

Pyridopyrrolizine and pyridoindolizine derivatives are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma.